Our Targeted Approach
Using a systems biology approach, we are attacking the metabolism of cancer cells on multiple levels.
First-in-class drug targeting metabolic dysfunction in cancer cells that is Phase II ready.
Ability to improve all current classes of oncology therapeutics (platinum-based, check-point inhibitors and immuno-oncology.
Market disrupting technology with no competition in the metabolic stabilization therapeutic area.